2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents

      , , , ,
      JCI Insight
      American Society for Clinical Investigation

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d2766270e188"> <b>BACKGROUND.</b> Excessive insulin secretion may lead to glucose dysregulation. Our aim was to identify primary (independent of insulin resistance) insulin hypersecretion in subjects with normal glucose tolerance and its role in the progression of dysglycemia. </p><p id="d2766270e193"> <b>METHODS.</b> In 1,168 adults, insulin secretion rate (ISR) and β cell function were estimated by C-peptide modeling during an oral glucose tolerance test (OGTT) and an i.v. glucose tolerance test. Whole-body insulin sensitivity was measured by a hyperinsulinemic-euglycemic clamp. After regressing ISR on insulin sensitivity, subjects in the upper tertile of the distribution of residuals were defined as primary hypersecretors. This approach was applied to a biethnic cohort of 182 obese adolescents, who received an OGTT, a hyperglycemic, and a euglycemic clamp. </p><p id="d2766270e198"> <b>RESULTS.</b> Adult hypersecretors showed older age, more familial diabetes, sedentary lifestyle, increased fat mass, and worse lipid profile compared with the rest of the cohort, despite virtually identical BMI and insulin sensitivity. Insulin secretion was increased by 53% due to enhanced (+23%) β cell glucose sensitivity. Despite the resulting hyperinsulinemia, glucose tolerance was worse in hypersecretors among both adults and adolescents, coupled with higher indices of liver insulin resistance and increased availability of gluconeogenic substrates. At the 3-year follow-up, adult hypersecretors had increased incidence of impaired glucose tolerance/type 2 diabetes. </p><p id="d2766270e203"> <b>CONCLUSION.</b> Primary insulin hypersecretion, independent of insulin resistance, is associated with a worse clinical and metabolic phenotype in adults and adolescents and predicts deterioration of glucose control over time. </p><p id="d2766270e208"> <b>FUNDING. </b>The relationship between insulin sensitivity and cardiovascular disease (RISC) Study was partly supported by EU grant QLG1-CT-2001-01252. </p><p class="first" id="d2766270e214"> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/523b1a82-7dec-4131-a1c8-555585efd0b5/PubMedCentral/image/jciinsight-3-124912-g115.jpg"/> </div> </p><p class="first" id="d2766270e219">Primary insulin hypersecretion is associated with an adverse clinical and metabolic phenotype and predicts deterioration of glucose control over time in nondiabetic adults and adolescents. </p>

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Autonomic regulation of islet hormone secretion--implications for health and disease.

          B. Ahrén (2000)
          The pancreatic islets are richly innervated by parasympathetic, sympathetic and sensory nerves. Several different neurotransmitters are stored within the terminals of these nerves, both the classical neurotransmitters, acetylcholine and noradrenaline, and several neuropeptides. The neuropeptides, vasoactive intestinal polypeptide, pituitary adenlyate cyclase activating polypeptide and gastrin releasing peptide are constituents of the parasympathetic nerves, whereas the neuropeptides galanin and neuropeptide Y are localised to sympathetic nerve terminals. Furthermore, the neuropeptide calcitonin gene-related peptide is localised to sensory nerves and cholecystokinin is also an islet neuropeptide, although the nature of the cholecystokinin nerves is not established. Stimulation of the autonomic nerves and treatment with neurotransmitters affect islet hormone secretion. Thus, insulin secretion is stimulated by parasympathetic nerves or their neurotransmitters and inhibited by sympathetic nerves or their neurotransmitters. The islet autonomic nerves seem to be of physiological importance in mediating the cephalic phase of insulin secretion, in synchronising the islets to function as a unit allowing oscillations of islet hormone secretion, and in optimising islet hormone secretion during metabolic stress, e.g. hypoglycaemia and neuroglycopenia. The autonomic nerves could also be involved in the islet adaptation to insulin resistance with possible implication for the development of glucose intolerance and Type II (non-insulin-dependent) diabetes mellitus. It is concluded that islet innervation, through the contribution of all branches of the autonomic nerves and several different neurotransmitters is of importance both for the physiology and pathophysiology of the islets.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.

            The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI]
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The glucose-alanine cycle.

                Bookmark

                Author and article information

                Journal
                JCI Insight
                American Society for Clinical Investigation
                2379-3708
                December 20 2018
                December 20 2018
                December 20 2018
                December 20 2018
                : 3
                : 24
                Article
                10.1172/jci.insight.124912
                6338316
                30568042
                5aa79452-6701-4f62-84b7-ce03b22863ff
                © 2018
                History

                Comments

                Comment on this article